Company news
Ironwood Pharmaceuticals, Inc. news in 2024
Ironwood Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 12, 2024
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
November 6, 2024
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
October 27, 2024
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
October 23, 2024
Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
August 28, 2024
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
August 7, 2024
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
July 24, 2024
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
May 20, 2024
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
May 8, 2024
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
May 5, 2024
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
April 30, 2024
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
April 24, 2024
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
March 27, 2024
Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
February 28, 2024
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
February 22, 2024
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
February 14, 2024
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
January 31, 2024
Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
January 7, 2024
Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
January 7, 2024
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Calls in 2024
Decks in 2024
- ACG 2024 Annual Scientific Meeting
Conference · 12 slides · Oct 29, 2024
- Q2 2024 Earnings Presentation
Earnings · 21 slides · Aug 8, 2024
- Digestive Disease Week 2024
Conference · 26 slides · May 21, 2024
- Q1 2024 Earnings Presentation
Earnings · 22 slides · May 9, 2024
- Technical Presentation (February 2024)
Technical · 9 slides · Feb 29, 2024
- FY2023 Earnings Presentation
Earnings · 17 slides · Feb 15, 2024
- Fact Sheet (February 2024)
Fact sheet · 22 slides · February 2024
- 42nd Annual J.P. Morgan Healthcare Conference 2024
Conference · 44 slides · Jan 10, 2024